1. Bialkowska-Hobrzanska, H., Driman, D.K., Fletcher, R., Harry, V., Razvi, H., 2006. Expression of human telomerase reverse transcriptase, survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. Can. J. Urol., 13(1):1967–1974.
2. Bjellerup, P., Theodorsson, E., Jornvall, H., Kogner, P., 2000. Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours. Br. J. Cancer, 83(2):171–176. [doi:10.1054/bjoc.2000.1234]
3. Chen, C.D., Welsbie, D.S., Tran, C., Baek, S.H., Chen, R., Vessella, R., Rosenfeld, M.G., Sawyers, C.L., 2004. Molecular determinants of resistance to antiandrogen therapy. Nature Medicine, 10(1):33–39. [doi:10.1038/nm972]
4. D’Amico, A.V., 2001. Combined-modality staging for localized adenocarcinoma of the prostate. Oncology (Huntington), 15(8):1049–1059.
5. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., Thun, M.J., 2007. Cancer statistics, 2007. C. A. Cancer J. Clin., 57(1):43–66.